Author name: Eos Maliqi

Investment accelerates global adoption of Noxilizer’s terminal sterilization alternative that is validated, safe, scalable and sustainable for biopharmaceutical and medical device manufacturers | Hanover, Maryland — September 10, 2025 — Noxilizer, Inc. (“Noxilizer”), the leader in nitrogen dioxide-based terminal sterilization for biopharmaceutical and medical device products, today announced a growth capital financing of $30 million […]

This month, a Noxilizer customer received authorization from EMA for their biotech drug in a prefilled syringe using NO2 sterilization. This follows the first FDA approval in 2024. There are other biotech drug submissions being reviewed at both the FDA and EMA. More approvals are expected this year.

The FDA recently approved a combination product using Noxilizer’s NO2 sterilization process. This is a biotech drug delivered in a prefilled syringe. The biotech company chose NO2 over other sterilization methods because of the ultra-low temperature sterilization process, minimum vacuum option and low to no residuals – all maintaining drug integrity. There are other products currently in